Novel strategies against multidrug resistance mediated by p-glycoprotein

S. Casco, E. Soto-Vega

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

P-glycoprotein (P-gp) is an ATP-binding cassette (ABC) protein that mediates the ATP-dependent efflux of hydrophobic toxins. Physiologically, P-gp excretes endogenous metabolites and other xenotoxic substrates into the urine, bile and feces. P-gp is a multidrug resistance (MDR) pump, which exports chemotherapeutic agents from target cells to the extracellular space. P-gp is considered an adverse factor in the prognosis of hematological and solid tumors because efflux of chemotherapeutic drugs reduces their intracellular levels, requiring higher doses to produce an effect equivalent to that before the P-gp overexpression. Effective P-gp modulators must inhibit P-gp activity, avoiding pharmacological interactions and toxicity. Nanoparticle-based advanced delivery systems have been recently studied, showing that these novel strategies can overcome MDR in some cancers.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalDrugs of the Future
Volume41
Issue number3
DOIs
StatePublished - 1 Mar 2016
Externally publishedYes

Keywords

  • Breast cancer
  • Chemotherapeutic
  • Colon cancer
  • Doxorubicin
  • Leukemia
  • Multidrug resistance
  • Nanoparticles
  • P-glycoprotein
  • Tariquidar
  • Verapamil

Fingerprint

Dive into the research topics of 'Novel strategies against multidrug resistance mediated by p-glycoprotein'. Together they form a unique fingerprint.

Cite this